Join the community - networking, discussion and more. Open to all.
More informationCould you write an interesting article for the RQA community?
More informationFees payable to the MHRA for 2021 to 2022
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.
Guidance for industry on preparing responses to good laboratory practice (GLP) and good clinical practice (GCP) inspection reports.
This toolkit is for Innovation Passport holders following the Innovative Licensing and Access Pathway (ILAP) and provides activities to support the design and development of medicines.
30 March 2021 Added new information on the inspector providing a verbal summary of GLP monitoring inspection findings. Added a link to a new page on responding to a GLP and GCP laboratory inspection report.
The MHRA GCP Stakeholder Engagement Meeting (StEM) now meets on an annual basis to provide a forum for discussion between the MHRA GCP inspectorate and represented stakeholders on key topics related to the conduct of clinical trials of investigational medicinal products....
The MHRA's latest post on it's inspectorate blog looks at how they have achieved over 750 remote inspections....
EMA’s human medicines committee (CHMP) recommended six medicines for approval at its February 2021 meeting.
EMA Management Board – highlights of March 2021 meeting Share
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 16-18 March 2021